Biogen and Novartis

Selected news for the company - Biogen, and the company - Novartis. We have 625 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
9/24/2021 Roche builds evidence for Evrysdi's benefits in younger SMA patients ... Biogen‚Aos Spinraza (nusinersen) ‚Ai an injectable antisense drug ‚Ai and Novartis‚Ao one-shot gene therapy Zolgensma (onasemnogene abeparvovec). Just five years earlier there were no therapies for SMA on the market. All three drugs are expensive, but Roche has priced Evrysdi at a discount to its rivals in a bid to claim market share. It Zolgensma costs about $2.1 million for a single shot of the gene therapy ...
9/24/2021 Roche builds evidence for Evrysdi's benefits in younger SMA patients ... Biogen‚Aos Spinraza (nusinersen) ‚Ai an injectable antisense drug ‚Ai and Novartis‚Ao one-shot gene therapy Zolgensma (onasemnogene abeparvovec). Just five years earlier there were no therapies for SMA on the market.All three drugs are expensive, but Roche has priced Evrysdi at a discount to its rivals in a bid to claim market share. ItZolgensma costs about $2.1 million for a single shot of the gene therapy ...
9/22/2021 Boston Labs and Germfree Launch Mobile Cell and Gene Therapy (CGT) Manufacturing Platform Business Wire ... Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio . Jon Mason, CEO of Boston Labs said: ‚AuAs the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued. Our pivotal partnership with Germfree Laboratories, Inc. enables Boston Labs to readily deploy mobile manufacturing platforms to any clinical site globally where ...
9/22/2021 The Ridgway Record ... Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio .Jon Mason, CEO of Boston Labs said: ‚AuAs the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued. Our pivotal partnership with Germfree Laboratories, Inc. enables Boston Labs to readily deploy mobile manufacturing platforms to any clinical site globally where ...
9/22/2021 Boston Labs and Germfree Launch Mobile Cell and Gene Therapy (CGT) Manufacturing Platform Yahoo News ... Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio .Jon Mason, CEO of Boston Labs said: "As the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued. Our pivotal partnership with Germfree Laboratories, Inc. enables Boston Labs to readily deploy mobile manufacturing platforms to any clinical site globally where ...
9/22/2021 Boston Labs and Germfree Launch Mobile Cell and Gene Therapy (CGT) Manufacturing Platform | Business Wire Business Wire ... Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio .Jon Mason, CEO of Boston Labs said: ‚AuAs the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued. Our pivotal partnership with Germfree Laboratories, Inc. enables Boston Labs to readily deploy mobile manufacturing platforms to any clinical site globally where ...
9/21/2021 Spinal Muscular Atrophy Treatment Market to Witness Growth by 2030 | Key Companies includes ‚Äì Novartis, Cytokinetics, Astellas, Biogen, Novartis, Roche, PTC Therapeutics and Others Spinal Muscular Atrophy Treatment Market to Witness Growth by 2030 Key Companies includes ‚Ai Novartis, Cytokinetics, Astellas, Biogen, Novartis, Roche, PTC Therapeutics and Others The Spinal Muscular Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best ...
9/14/2021 Gene Therapy on Neurological Diseases Market With A Growing CAGR During 2021-2028| Biogen,Novartis,Sarepta Therapeutics PRSync Gene Therapy on Neurological Diseases Market With A Growing CAGR During 2021-2028 Biogen,Novartis,Sarepta Therapeutics [reportsandmarkets] - Tuesday, September 14, 2021. Global Gene Therapy on Neurological Diseases Market: Trends Estimates High Demand by 2027 This report on the Global Gene Therapy on Neurological Diseases MARKET is the latest released report providing a detailed analysis of the Gene Therapy on Neurological Diseases industry [. It provides an insight into the overall structure ...
9/12/2021 Featured Video: Neuromuscular Disease Awareness ... Biogen‚Aos nusinersen (Spinraza) ‚Ai the first disease-modifying therapy for SMA, which was approved in December 2016‚Ai and Novartis AveXis‚Ao onasemnogene abeparvovec-xioi (Zolgensma) ‚Ai a gene-replacement therapy for SMA that was approved in May 2019 ‚Ai patients will have access to another promising therapy. SMA is caused by a mutated or missing survival motor neuron 1 gene (SMN1), which prevents the body from making enough ...
9/2/2021 Gene Therapy Market Latest Trends, Revenue Growth Rate And Application Scope ... Novartis AG - Spark Therapeutics, Inc. - Biogen - Gilead Sciences, Inc - Amgen, Inc. - Jazz Pharmaceuticals, Inc. - Sarepta Therapeutics - GlaxoSmithKline plc - Other Prominent Players Some major points from Table of Content: - IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and Assumptions - Executive Summary - Market DynamicsMarket DriversMarket RestraintsMarket Opportunities - Key InsightsOverview of Regulatory ScenarioKey Product Launches/RecallsPipeline AnalysisScientific Advancements in Gene TherapyKey Industry developments ‚Ai Mergers, Acquisitions and PartnershipsPatent AnalysisCOVID-19 Impact on Gene Therapy Market - Global Gene ...
8/30/2021 Cancer Treatment Drugs Market 2020 Demand with Global Forecast by Top Leading Players: Biogen Idec, Merck & Co., Novartis and Others to 2025 Cancer Treatment Drugs Market 2020 Demand with Global Forecast by Top Leading Players: Biogen Idec, Merck & Co., Novartis and Others to 2025 Global Cancer Treatment Drugs Market 2020 report endows information on the business scenario with which it can be integrated for business strategies to succeed. According to this report, the global Cancer Treatment Drugs market is expected to observe an inclining development rate during the forecast period to 2025 ...
8/27/2021 Neurodegenerative Disease Treatment Market - Market estimates and forecast 2016-2031 PRSync ... Novartis AG, Pfizer Inc., Merck Serono, Biogen Inc., Teva Pharmaceutical Industries Ltd., UCB, C.H. Boehringer Sohn AG & Ko. KG, Sanofi S.A., GlaxoSmithKline, and Neuro-Hitech Inc. https://bit.ly/3DjFSki About Coherent Market Insights Pvt. Ltd. Coherent Market Insights (CMI) is a global market intelligence and consulting organization focused on assisting plethora of clients achieve transformational growth by helping them make critical business decisions. The company is headquartered in India, having ...
8/27/2021 Trigeminal Neuralgia Treatment Market Rapid Development by Manufactures, Types, Applications and Regions to 2026 ... Biogen, Inc., Merz Pharma GmbH & Co., Abbott Laboratories, Trigemina Inc., Pfizer Inc., Novartis, and GlaxoSmithKline Plc.‚Au Some Table of Content (ToC) points of Trigeminal Neuralgia Treatment Industry Report: Trigeminal Neuralgia Treatment Market Research Objective and Assumption. Trigeminal Neuralgia Treatment Market Purview ‚Ai Report Description, Executive Summary, and Coherent Opportunity Map (COM). Trigeminal Neuralgia Treatment Market Dynamics, Regulations, and Trends Analysis ‚Ai Market Dynamics, Regulatory Scenario, Industry Trend, Merger and ...
8/25/2021 Global Drugs for Oncology Market Clinical Aspects, Reviews and Analysis 2021 to 2026 ... Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences Segment by Type, the Drugs for Oncology market is segmented into Chemotherapy Targeted Therapy Immunotherapy (Biologic Therapy) Hormonal Therapy Others Segment by Application, the Drugs for Oncology market is segmented into Blood Cancer Breast Cancer Gastrointestinal Cancer Prostate Cancer Respiratory/Lung Cancer ...
8/24/2021 Global Protein Drugs Market (2021 to 2026) – Featuring Abbvie, Amgen and CSL Among Others – ResearchAndMarkets.com | Financial Buzz ... Biogen Biomarin Pharmaceutical Inc. Biotest Bristol-Myers Squibb CSL Ltd. Eli Lilly F. Hoffmann-La Roche Ag Fresenius Kabi Glaxosmithkline Grifols S.A. Johnson & Johnson Merck & Co., Inc. Merck Kgaa Novartis Ag Novo Nordisk Ag Octapharma Ag Pfizer Inc. Sandoz Sanofi S.A. Seagen Takeda Pharmaceutical Co., Ltd. UCB Co. This report will focus on protein drugs, classification and manufacturing technologies. The protein drugs market can be classified into peptide hormones, monoclonal ...
8/23/2021 Biotechnology Market 2020 Future Set to Massive Growth with High CAGR value | Market Players: AstraZeneca,Gilead Sciences, Inc. ,CELGENE CORPORATION,Biogen PRSync ... Biotechnology Market 2020 Future Set to Massive Growth with High CAGR value Market Players: AstraZeneca,Gilead Sciences, Inc. ,CELGENE CORPORATION,Biogen Global Biotechnology market 2020-2026 in-depth study accumulated to supply latest insights concerning acute ... Novo Nordisk A/S,Merck & Co.,Johnson & Johnson Services, Inc.,Novartis AG,Sanofi,F. Hoffmann-La Roche Ltd.,Pfizer, Inc.,Lonza GET SAMPLE COPY OF THIS REPORT: https://www.datalibraryresearch.com/sample-request/biotechnology-market-2521?utm ...
8/20/2021 2-Hydroxy-2-Methylpropiophenone(Photoinitiator-1173) Market: In-depth Analysis of the Global Industry with Future Estimations ... Novartis Synthon Pharmaceuticals Teva Pharmaceutical Industries LG Life Sciences Celltrion Biocon Hospira Merck Group Biogen idec, Inc. Genentech (Roche Group) Segment by Regions North America Europe China Japan Southeast Asia India Segment by Type Human growth hormone Erythropoietin Monoclonal antibodies Insulin Interferon Granulocyte-Colony Stimulating Factor Peptide Others Segment by Application Blood disorders Oncology diseases Chronic and autoimmune diseases Growth hormone deficiencies Others Make An Enquiry About This Report @ https ...
8/13/2021 Neurodegenerative Disease Treatment Market Highlights 2020 – Industry Development by 2026, Detailed Analysis Research Report ... Novartis AG, Pfizer Inc., Merck Serono, Biogen Inc., Teva Pharmaceutical Industries Ltd., UCB, C.H. Boehringer Sohn AG & Ko. KG, Sanofi S.A., GlaxoSmithKline, and Neuro-Hitech Inc. In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development. The complete research ...
8/13/2021 Zacks Investment Research Upgrades Ionis Pharmaceuticals (NASDAQ:IONS) to ‚ÄúHold‚Äù - The Cerbat Gem ... Biogen, has witnessed strong patient uptake, which in turn brings in significant royalty revenues for Ionis. The company has a broad pipeline of partnered programs with Biogen, Pfizer, Novartis and others. It to diversify revenues away from Spinraza royalties. Several data readouts are scheduled in 2021/2022, which could be catalysts for the stock. However, the competitive environment for Ionis‚Ao product/pipeline, mainly Spinraza is intense. Spinraza‚Aos sales are ...
8/11/2021 Cell and Gene Therapy Market Therapeutic Survey Reviews, Analysis 2030 | Biogen Inc.; Novartis AG; Gilead Sciences; Ionis Pharmaceuticals, Inc. ... Biogen Inc.; Novartis AG; Gilead Sciences; Ionis Pharmaceuticals, Inc.; Alnylam Pharmaceuticals Inc. The global cell and gene therapy market reached a value of nearly $4,390.3 million in 2020, having increased at a compound annual growth rate (CAGR) of 25.5% since 2015. The market is expected to grow from $4,390.3 million in 2020 to $15,482.3 million in 2025 at a rate of 28.7%. The market is then expected to grow at ...
8/11/2021 Global Oncology Small Molecule Drugs Market Report 2020 ... Novartis Pfizer Celgene Bristol-Myers Squibb Amgen Johnson & Johnson AbbVie Sanofi Takeda Eli Lilly Bayer AstraZeneca Astellas Merck Biogen Idec Eisai Teva Otsuka Ipsen Gilead Sciences Exelixis BIS reports covers key roles in analyzing the industry outlook and let understand the prominent vendors about their strategies and future plans for the betterment of the market in the near future. Furthermore, the report also covers an ultimate goal of market target ...
8/10/2021 Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to ‚ÄúHold‚Äù by Zacks Investment Research - Slater Sentinel ... Biogen, has witnessed strong patient uptake, which in turn brings in significant royalty revenues for Ionis. The company has a broad pipeline of partnered programs with Biogen, Pfizer, Novartis and others. It to diversify revenues away from Spinraza royalties. Several data readouts are scheduled in 2021/2022, which could be catalysts for the stock. However, the competitive environment for Ionis‚Ao product/pipeline, mainly Spinraza is intense. Spinraza‚Aos sales are ...
8/10/2021 Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Zacks Investment Research ... Biogen, has witnessed strong patient uptake, which in turn brings in significant royalty revenues for Ionis. The company has a broad pipeline of partnered programs with Biogen, Pfizer, Novartis and others. It to diversify revenues away from Spinraza royalties. Several data readouts are scheduled in 2021/2022, which could be catalysts for the stock. However, the competitive environment for Ionis‚Ao product/pipeline, mainly Spinraza is intense. Spinraza‚Aos sales are ...
8/9/2021 Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Hold at Zacks Investment Research - Transcript Daily ... Biogen, has witnessed strong patient uptake, which in turn brings in significant royalty revenues for Ionis. The company has a broad pipeline of partnered programs with Biogen, Pfizer, Novartis and others. It to diversify revenues away from Spinraza royalties. Several data readouts are scheduled in 2021/2022, which could be catalysts for the stock. However, the competitive environment for Ionis‚Ao product/pipeline, mainly Spinraza is intense. Spinraza‚Aos sales are ...
8/3/2021 Global Acute Coronary Syndrome Market | Global Acute Coronar… | Flickr ... Novartis AG, Amgen Inc., AbbVie Inc., Portals Pharma, Inc., AstraZeneca, GlaxoSmithKline plc, Eli Lilly and Company, DAIICHI SANKYO COMPANY LIMITED, Sanofi, Daiichi Sankyo, Inc., Pfizer Inc., Baxter, DCVMN, Serum Institute of India Pvt. Ltd., Biogen among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America separately. DBMR analysts understand competitive strengths and provide ...